scholarly journals Is cardiac wasting accompanied by skeletal muscle loss in breast cancer patients receiving anticancer treatment?

2017 ◽  
Vol 8 (5) ◽  
pp. 851-852 ◽  
Author(s):  
Junichi Ishida ◽  
Masakazu Saitoh ◽  
Jochen Springer
Keyword(s):  
Breast Cancer ◽  
Skeletal Muscle ◽  
Cancer Patients ◽  
Muscle Loss ◽  
Breast Cancer Patients ◽  
Anticancer Treatment ◽  
Skeletal Muscle Loss

Skeletal muscle loss and prognosis of breast cancer patients

2017 ◽  
Vol 25 (7) ◽  
pp. 2221-2227 ◽  
Author(s):  
Yoshiko Kubo ◽  
Tateaki Naito ◽  
Keita Mori ◽  
Gakuji Osawa ◽  
Etsuko Aruga
Keyword(s):  
Breast Cancer ◽  
Skeletal Muscle ◽  
Cancer Patients ◽  
Muscle Loss ◽  
Breast Cancer Patients ◽  
Skeletal Muscle Loss

scholarly journals Association between Skeletal Muscle Loss and the Response to Neoadjuvant Chemotherapy for Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1806
Author(s):  
Byung Min Lee ◽  
Yeona Cho ◽  
Jun Won Kim ◽  
Sung Gwe Ahn ◽  
Jee Hung Kim ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Skeletal Muscle ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Muscle Loss ◽  
Breast Cancer Patients ◽  
Skeletal Muscle Index ◽  
Skeletal Muscle Loss ◽  
The Impact ◽  
Response To Neoadjuvant Chemotherapy

There are no means to predict patient response to neoadjuvant chemotherapy (NAC); the impact of skeletal muscle loss on the response to NAC remains undefined. We investigated the association between response to chemotherapy and skeletal muscle loss in breast cancer patients. Patients diagnosed with invasive breast cancer who were treated with NAC, surgery, and radiotherapy were analyzed. We quantified skeletal muscle loss using pre-NAC and post-NAC computed tomography scans. The response to treatment was determined using the Response Evaluation Criteria in Solid Tumors. We included 246 patients in this study (median follow-up, 28.85 months). The median age was 48 years old (interquartile range 42–54) and 115 patients were less than 48 years old (46.7%). Patients showing a complete or partial response were categorized into the responder group (208 patients); the rest were categorized into the non-responder group (38 patients). The skeletal muscle mass cut-off value was determined using a receiver operating characteristic curve; it showed areas under the curve of 0.732 and 0.885 for the pre-NAC and post-NAC skeletal muscle index (p < 0.001 for both), respectively. Skeletal muscle loss and cancer stage were significantly associated with poor response to NAC in locally advanced breast cancer patients. Accurately measuring muscle loss to guide treatment and delaying muscle loss through various interventions would help enhance the response to NAC and improve clinical outcomes.

Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in breast cancer patients

2021 ◽  
Vol 58 ◽  
pp. 27-34
Author(s):  
Marco Invernizzi ◽  
Konstantinos Venetis ◽  
Elham Sajjadi ◽  
Roberto Piciotti ◽  
Alessandro de Sire ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Muscle Loss ◽  
Breast Cancer Patients ◽  
Exercise Rehabilitation ◽  
Volumetric Muscle Loss

Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy

Surgery Today ◽  
2019 ◽  
Vol 49 (12) ◽  
pp. 1022-1028 ◽  
Author(s):  
Naoki Kamitani ◽  
Kazuhiro Migita ◽  
Sohei Matsumoto ◽  
Kohei Wakatsuki ◽  
Tomohiro Kunishige ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Esophageal Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Muscle Loss ◽  
Long Term Outcomes ◽  
Skeletal Muscle Loss

scholarly journals A moderately high protein diet and 4’ isometric exercises efficacy in breast cancer patients treated with antiestrogenic medication

2017 ◽  
Vol 12 (2) ◽  
pp. 83-90
Author(s):  
Diana Violeta ARTENE ◽  
◽  
Cristian Ioan BORDEA ◽  
Alexandru BLIDARU ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Isometric Exercise ◽  
High Protein Diet ◽  
Diet Group ◽  
High Protein ◽  
Protein Diet ◽  
Muscle Loss ◽  
Breast Cancer Patients ◽  
Exercise Protocol

Many breast cancer patients gain weight during treatment increasing recurrence, oncology specific mortality and general mortality risks. Breast cancer diagnosis and treatment overthrow patients’ lifestyle aggravating sedentariness and any preexisting weight gain causes like insulin and leptin resistance, dysbiosys and dyslipidemia. The aim of this study is to evaluate the efficiency of a moderately high protein diet – based on foods naturally high in proteins, omega-3 fatty acids, calcium, probiotics and prebiotics – and of an isometric exercise protocol to generate fat loss without muscle loss in ER+ breast cancer patients taking antiestrogenic treatment. We randomized 50 ER+ breast cancer patients – taking either Tamoxifen or Aromatase Inhibitors (AI) after surgery and chemotherapy – to follow a high protein diet, or a high protein diet and 4’ isometric exercises for 12 weeks. Patients were instructed to eat only when hungry and to keep a food journal. We measured weight and body composition with a bioelectrical impedance scale after checking for hydration status. The diet group lost 2.17 ± 2.42% subcutaneus fat (p = 0,000) with no muscle loss, and there was no statistical difference between patients taking Tamoxifen or AI regarding body composition evolution. The diet + isometric exercise group lost 2.2 more pounds than the diet group and 0.66 ± 0.91% visceral fat (p = 0,001) also with no muscle loss. AI patients from the diet and exercise grup did not improve muscle mass – maybe because of the musculoskeletal impact of AI medication. In conclusion, a moderately high protein diet can decrease body fat in ER+ breast cancer patients on antiestrogenic medication. Adding a daily minimal exercise protocol to a high protein diet decreases visceral fat – which is more hormonally active. And resistance-training exercises are more appropriate than isometric exercises for patients on AI.

Sign in / Sign up

Export Citation Format

Share Document